TXG logo

10x Genomics Inc. (TXG)

$56.30

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on TXG

Market cap

$7.41B

EPS

-0.52

P/E ratio

--

Price to sales

17.03

Dividend yield

--

Beta

2.032617

Price on TXG

Previous close

$54.99

Today's open

$55.47

Day's range

$52.67 - $56.73

52 week range

$15.18 - $102.81

Profile about TXG

CEO

Serge Saxonov

Employees

1178

Headquarters

Pleasanton, CA

Exchange

Nasdaq Global Select

Shares outstanding

131534189

Issue type

Common Stock

TXG industries and sectors

Healthcare

Biotechnology & Life Sciences

News on TXG

10x Genomics Expands Global Research in Blood-Based Diagnostics for Autoimmune Disease with Two New Collaborations

Collaborations with Charité and DRFZ, and with Seoul National University, aim to identify biomarkers of disease activity and treatment response using 10x's Flex Apex platform PLEASANTON, Calif., Nov. 16, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, today announced two new research collaborations focused on identifying blood-based biomarkers of disease activity and treatment response for autoimmune disease.

news source

PRNewsWire • Nov 16, 2026

news preview

10x Genomics' Xenium Platform to Support Breast Cancer Biomarker Study

TXG's Xenium platform is set to power a 500-patient breast cancer biomarker study, expanding its oncology research footprint and precision diagnostics potential.

news source

Zacks Investment Research • Nov 12, 2026

news preview

Shanghai Precision Diagnostics and Fudan University Shanghai Cancer Center Launch Breast Cancer Biomarker Study Using 10x Genomics' Xenium Platform

Study aims to identify biomarkers that could predict how patients with breast cancer respond to neoadjuvant therapy PLEASANTON, Calif., Nov. 10, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, today announced that Fudan University Shanghai Cancer Center (FUSCC) and Shanghai Precision Diagnostics Co. Ltd (SPDx), will deploy its Xenium platform in a 24-month study.

news source

PRNewsWire • Nov 10, 2026

news preview

What 10x Genomics (TXG) Said on Its Q3 Earnings Call

10x Genomics NASDAQ: TXG raised its full-year revenue outlook after reporting modest third-quarter growth and increased its shipment target for its new Atera spatial biology platform.

news source

MarketBeat • Nov 6, 2026

news preview

TXG Q3 Earnings Call Highlights Atera Launch and Raised Outlook

10x Genomics raises its 2026 revenue outlook on strong Atera demand and spatial consumables growth, but production constraints and margin pressure remain challenges.

news source

Zacks Investment Research • Nov 6, 2026

news preview

10x Genomics Launches Sentira AI Tool to Simplify Cell Analysis

TXG launches Sentira Single Cell, a Claude-powered AI tool to simplify complex data analysis, accelerate research and unlock recurring revenue potential.

news source

Zacks Investment Research • Nov 6, 2026

news preview

10x Genomics, Inc. (TXG) Q3 2026 Earnings Call Transcript

10x Genomics, Inc. (TXG) Q3 2026 Earnings Call Transcript

news source

Seeking Alpha • Nov 6, 2026

news preview

10x Genomics Reports Third Quarter 2026 Financial Results

PLEASANTON, Calif., Nov. 5, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, today reported financial results for the third quarter ended September 30, 2026.

news source

PRNewsWire • Nov 5, 2026

news preview

10x Genomics (TXG) Reports Q3 Loss, Beats Revenue Estimates

10x Genomics (TXG) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to a loss of $0.22 per share a year ago.

news source

Zacks Investment Research • Nov 5, 2026

news preview

Compared to Estimates, 10x Genomics (TXG) Q3 Earnings: A Look at Key Metrics

The headline numbers for 10x Genomics (TXG) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

news source

Zacks Investment Research • Nov 6, 2026

news preview

¹ Disclosures

Get started with M1

Invest in 10x Genomics Inc.

Open an M1 investment account to buy and sell 10x Genomics Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in TXG on M1